BOSTON SCIENTIFIC CORPORATION

Boston Scientific receives FDA approval for Farawave Nav ablation catheter and 510(k) clearance for Faraview software, enhancing cardiac ablation procedures with Farapulse PFA system, integrating mapping and therapy delivery.

Boston Scientific received FDA approval for the FARAWAVE™ NAV Ablation Catheter and 510(k) clearance for FARAVIEW™ Software, enhancing visualization in cardiac ablation procedures with the FARAPULSE™ PFA System, compatible with OPAL HDx™ Mapping System.

Electrotherapy, using electrical impulses to relax muscles, improve blood flow, repair tissues, and encourage bone formation, sees increased global demand due to its application in various ailments. Technological advancements in interferential therapy, ultrasound therapy, and transcutaneous electrical nerve stimulation are driving market growth. Key market players include AliMedInc, Cogentix Medical Inc, St. Jude Medical Inc, and Zynex Medical. The Americas dominate the market, with a CAGR of 5.53%, driven by sports-related injuries and advanced healthcare systems.

The Global Drug Device Combination Products Market is projected to reach USD 174.4 billion in 2024 and USD 389.7 billion by 2033 at a CAGR of 9.3%. The US market is expected to grow from USD 59.1 billion in 2024 to USD 125.6 billion by 2033 at a CAGR of 8.7%. Key drivers include technological advancements and rising chronic diseases. Major players include Medtronic, Abbott Laboratories, and Boston Scientific.

Senseonics and Ascensia receive FDA clearance for Eversense 365 CGM system, expected to launch in Q4 2024, aiming to integrate with insulin pumps. Despite the clearance, SENS stock dropped 20% following the announcement.

Boston Scientific receives FDA approval to expand INGEVITY™+ Pacing Leads' indication for conduction system pacing and sensing of the left bundle branch area, offering an alternative to traditional right ventricular pacing for treating symptomatic bradycardia.

The global pacemaker devices market is projected to grow at a CAGR of 3.8% from 2024 to 2034, reaching $6.9 billion by 2034, driven by personalized medicine, telemedicine, and environmental sustainability.

The implantable medical devices market, driven by chronic disease prevalence, aging population, and tech advancements, is projected to grow from $126.3 billion in 2024 to $146.81 billion by 2031, with a CAGR of 6.8%. North America leads with a 43% share due to advanced healthcare infrastructure. Key drivers include favorable reimbursement policies and technological innovations like smart implants and 3D printing. Challenges include high costs, regulatory hurdles, and device complications.